Costs of Care in Relation to Alzheimer's Disease Severity in Sweden: A National Registry-Based Cohort Study.
Journal
PharmacoEconomics
ISSN: 1179-2027
Titre abrégé: Pharmacoeconomics
Pays: New Zealand
ID NLM: 9212404
Informations de publication
Date de publication:
01 Nov 2024
01 Nov 2024
Historique:
accepted:
30
09
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
aheadofprint
Résumé
The advancement of diagnostic and therapeutic interventions in early Alzheimer's disease (AD) has demanded the economic evaluation of such interventions. Resource utilization and cost estimates in early AD and, more specifically, the amyloid-positive population are still lacking. We aimed to provide cost estimates in AD in relation to disease severity and compare these with the control population. We also aimed to provide cost estimates for a subset of the AD population with both clinical diagnosis and amyloid-positive confirmation. This was a retrospective longitudinal analysis of resource utilization using data from national registries. A cohort from the national Swedish registry for cognitive/dementia disorders (SveDem) includes all clinically diagnosed AD between 2013 and 2020. The study population included 31,951 people with AD and 63,902 age- and sex-matched controls (1:2). The population was followed until death, the end of December 2020, or 2 years from the last clinic visit. Direct medical and social costs were estimated from other national registries. Direct medical costs include costs for medications and inpatient and outpatient clinical visits. Direct social costs include costs for institutionalization, home care, short-term care, support for daytime activities, and housing support. Mean annual costs and 95% confidence intervals were obtained by bootstrapping, presented in 2021 Swedish Krona (SEK) (1 SEK = 0.117 USD, 1 SEK = 0.0985 EUR in 2021), and disaggregated by AD severity, cost component, sex, age group, and care setting. Mean annual costs for individuals with clinically diagnosed AD were SEK 99,906, SEK 290,972, SEK 479,524, and SEK 795,617 in mild cognitive impairment (MCI), mild, moderate, and severe AD. The mean annual costs for the population with both clinical diagnosis and amyloid-positive AD confirmation (N = 5610) were SEK 57,625, SEK 179,153, SEK 333,095, and SEK 668,073 in MCI, mild, moderate, and severe AD, respectively. The mean annual costs were higher in institutionalized than non-institutionalized patients, females than males, and older than younger age groups. Inpatient and drug costs were similar in all AD severity stages, but outpatient costs decreased with AD severity. Costs for institutionalization, home care, support for daytime activities, and short-term care increased with AD severity, whereas the cost of housing support decreased with AD severity. This is the first study estimating annual costs in people with AD from MCI to severe AD, including those for the amyloid-positive population. The study provides cost estimates by AD severity, cost components, care settings, sex, and age groups, allowing health economic modelers to apply the costs based on different model structures and populations.
Sections du résumé
BACKGROUND
BACKGROUND
The advancement of diagnostic and therapeutic interventions in early Alzheimer's disease (AD) has demanded the economic evaluation of such interventions. Resource utilization and cost estimates in early AD and, more specifically, the amyloid-positive population are still lacking. We aimed to provide cost estimates in AD in relation to disease severity and compare these with the control population. We also aimed to provide cost estimates for a subset of the AD population with both clinical diagnosis and amyloid-positive confirmation.
MATERIALS AND METHODS
METHODS
This was a retrospective longitudinal analysis of resource utilization using data from national registries. A cohort from the national Swedish registry for cognitive/dementia disorders (SveDem) includes all clinically diagnosed AD between 2013 and 2020. The study population included 31,951 people with AD and 63,902 age- and sex-matched controls (1:2). The population was followed until death, the end of December 2020, or 2 years from the last clinic visit. Direct medical and social costs were estimated from other national registries. Direct medical costs include costs for medications and inpatient and outpatient clinical visits. Direct social costs include costs for institutionalization, home care, short-term care, support for daytime activities, and housing support. Mean annual costs and 95% confidence intervals were obtained by bootstrapping, presented in 2021 Swedish Krona (SEK) (1 SEK = 0.117 USD, 1 SEK = 0.0985 EUR in 2021), and disaggregated by AD severity, cost component, sex, age group, and care setting.
RESULTS
RESULTS
Mean annual costs for individuals with clinically diagnosed AD were SEK 99,906, SEK 290,972, SEK 479,524, and SEK 795,617 in mild cognitive impairment (MCI), mild, moderate, and severe AD. The mean annual costs for the population with both clinical diagnosis and amyloid-positive AD confirmation (N = 5610) were SEK 57,625, SEK 179,153, SEK 333,095, and SEK 668,073 in MCI, mild, moderate, and severe AD, respectively. The mean annual costs were higher in institutionalized than non-institutionalized patients, females than males, and older than younger age groups. Inpatient and drug costs were similar in all AD severity stages, but outpatient costs decreased with AD severity. Costs for institutionalization, home care, support for daytime activities, and short-term care increased with AD severity, whereas the cost of housing support decreased with AD severity.
CONCLUSIONS
CONCLUSIONS
This is the first study estimating annual costs in people with AD from MCI to severe AD, including those for the amyloid-positive population. The study provides cost estimates by AD severity, cost components, care settings, sex, and age groups, allowing health economic modelers to apply the costs based on different model structures and populations.
Identifiants
pubmed: 39485581
doi: 10.1007/s40273-024-01443-2
pii: 10.1007/s40273-024-01443-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : VINNOVA
ID : 2021-02680
Organisme : Innovative Health Initiative Joint Undertaking
ID : 101112145
Informations de copyright
© 2024. The Author(s).
Références
2022 Alzheimer’s disease facts and figures. Alzheimers Dement. 2022;18(4), 700–789. https://doi.org/10.1002/ALZ.12638
Wimo A, Seeher K, Cataldi R, Cyhlarova E, Dielemann JL, Frisell O, et al. The worldwide costs of dementia in 2019. Alzheimers Dement. 2023;19(7):2865–73. https://doi.org/10.1002/alz.12901 .
doi: 10.1002/alz.12901
pubmed: 36617519
World Health Organization. (2021). Global status report on the public health response to dementia. Geneva: World Health Organization. https://www.who.int/publications/i/item/9789240033245 . Accessed 29 Apr 2024.
Paroni G, Bisceglia P, Seripa D. Understanding the amyloid hypothesis in Alzheimer’s disease. J Alzheimers Dis. 2019;68(2):493–510. https://doi.org/10.3233/JAD-180802 .
doi: 10.3233/JAD-180802
pubmed: 30883346
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–9. https://doi.org/10.1016/J.JALZ.2011.03.008 .
doi: 10.1016/J.JALZ.2011.03.008
pubmed: 21514249
Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357–67. https://doi.org/10.1016/S1474-4422(13)70044-9 .
doi: 10.1016/S1474-4422(13)70044-9
pubmed: 23477989
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Budd Haeberlein S, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62. https://doi.org/10.1016/j.jalz.2018.02.018 .
doi: 10.1016/j.jalz.2018.02.018
pubmed: 29653606
Schachter AS, Davis KL. Alzheimer’s diseasse. Dialog Clin Neurosci. 2000;2(2):91–100.
doi: 10.31887/DCNS.2000.2.2/asschachter
Frisell O, Jönsson L, Wimo A (2023) Demenssjukdomarnas samhällskostnader i sverige 2019. https://www.demenscentrum.se/sites/default/files//dokument/FORSKNING/demenssjukd_samhallskostn_2019.pdf . Accessed 29 Apr 2024.
Schaller S, Mauskopf J, Kriza C, Wahlster P, Kolominsky-Rabas PL. The main cost drivers in dementia: a systematic review. Int J Geriatr Psychiatry. 2015. https://doi.org/10.1002/gps.4198 .
doi: 10.1002/gps.4198
pubmed: 25320002
Wübker A, Zwakhalen SMG, Challis D, Suhonen R, Karlsson S, Zabalegui A, et al. Costs of care for people with dementia just before and after nursing home placement: primary data from eight European countries. Eur J Health Econ. 2015;16(7):689–707. https://doi.org/10.1007/S10198-014-0620-6 .
doi: 10.1007/S10198-014-0620-6
pubmed: 25069577
Gómez Maldonado L, De Mora-Figueroa R, López-Angarita A, Maravilla-Herrera P, Merino M. Cost of patients with Alzheimer’s disease in spain according to disease severity. Pharmacoecon Open. 2024;8(1):103–14. https://doi.org/10.1007/s41669-023-00451-w .
doi: 10.1007/s41669-023-00451-w
pubmed: 37966711
Jönsson L, Tate A, Frisell O, Wimo A, Se LJ. The costs of dementia in Europe: an updated review and meta-analysis. Pharmacoeconomics. 2023;41(1):59–75. https://doi.org/10.1007/s40273-022-01212-z .
doi: 10.1007/s40273-022-01212-z
pubmed: 36376775
Cantarero-Prieto D, Leon PL, Blazquez-Fernandez C, Juan PS, Cobo CS. The economic cost of dementia: a systematic review. Dementia (London). 2020;19(8):2637–57. https://doi.org/10.1177/1471301219837776/FORMAT/EPUB .
doi: 10.1177/1471301219837776/FORMAT/EPUB
pubmed: 30909718
Tay LX, Ong SC, Tay LJ, Ng T, Parumasivam T. Economic burden of Alzheimer’s disease: a systematic review. Value Health Region Issues. 2024;40:1–12. https://doi.org/10.1016/j.vhri.2023.09.008 .
doi: 10.1016/j.vhri.2023.09.008
Jönsson L, Jönhagen ME, Kilander L, Soininen H, Hallikainen M, Waldemar G. Determinants of costs of care for patients with Alzheimer’s disease. Int J Geriatr Psychiatry. 2006;21(5):449–59. https://doi.org/10.1002/gps.1489 .
doi: 10.1002/gps.1489
pubmed: 16676288
Mesterton J, Wimo A, By Å, Langworth S, Winblad B, Jönsson L. Cross sectional observational study on the societal costs of Alzheimer’s disease. Curr Alzheimer Res. 2010;7(4):358–67.
doi: 10.2174/156720510791162430
pubmed: 19939223
Gustavsson A, Bergvall N, Kolasa K, Wimo A, Winblad B, Jönsson L. Predictors of costs of care in Alzheimer’s disease: a multinational sample of 1222 patients. Alzheimers Dement. 2011;7(3):318–27. https://doi.org/10.1016/j.jalz.2010.09.001 .
doi: 10.1016/j.jalz.2010.09.001
pubmed: 21575872
Wimo A, Jönsson L, Fratiglioni L, Sandman PO, Gustavsson A, Sköldunger A, Johansson L. The societal costs of dementia in Sweden 2012—relevance and methodological challenges in valuing informal care. Alzheimer’s Res Ther. 2016. https://doi.org/10.1186/s13195-016-0215-9 .
doi: 10.1186/s13195-016-0215-9
Persson S, Saha S, Gerdtham UG, Toresson H, Trépel D, Jarl J. Healthcare costs of dementia diseases before, during and after diagnosis: longitudinal analysis of 17 years of Swedish register data. Alzheimers Dement. 2022;18(12):2560–9. https://doi.org/10.1002/alz.12619 .
doi: 10.1002/alz.12619
pubmed: 35189039
Zilling J, Gerdtham UG, Jarl J, Saha S, Persson S. The formal care costs of dementia: a longitudinal study using Swedish register data. Eur J Health Econ. 2024. https://doi.org/10.1007/s10198-024-01707-w .
doi: 10.1007/s10198-024-01707-w
pubmed: 39080093
Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255–63. https://doi.org/10.1016/S0140-6736(15)60461-5 .
doi: 10.1016/S0140-6736(15)60461-5
pubmed: 25771249
Barthélemy NR, Salvadó G, Schindler S, He Y, Janelidze S, Collij LE, et al. Highly accurate blood test for Alzheimer’s disease comparable or superior to clinical CSF tests. Nat Med. 2024. https://doi.org/10.1038/s41591-024-02869-z .
doi: 10.1038/s41591-024-02869-z
pubmed: 38890531
pmcid: 11186765
Janelidze S, Bali D, Ashton N, Barthélemy N, Vanbrabant J, Stoops E, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease. Brain. 2023;146(4):1592–601. https://doi.org/10.1093/brain/awac333 .
doi: 10.1093/brain/awac333
pubmed: 36087307
Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis. 2022;9(2):197–210. https://doi.org/10.14283/JPAD.2022.30 .
doi: 10.14283/JPAD.2022.30
pubmed: 35542991
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9–21. https://doi.org/10.1056/nejmoa2212948 .
doi: 10.1056/nejmoa2212948
pubmed: 36449413
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512–27. https://doi.org/10.1001/jama.2023.13239 .
doi: 10.1001/jama.2023.13239
pubmed: 37459141
pmcid: 10352931
Taipale H, Koponen M, Tanskanen A, Tolppanen AM, Tiihonen J, Hartikainen S. Drug use in persons with and without Alzheimer’s disease aged 90 years or more. Age Ageing. 2016;45(6):900–4. https://doi.org/10.1093/AGEING/AFW141 .
doi: 10.1093/AGEING/AFW141
pubmed: 27609205
Frahm-Falkenberg S, Ibsen R, Kjellberg J, Jennum P. Health, social and economic consequences of dementias: a comparative national cohort study. Eur J Neurol. 2016;23:1400–7. https://doi.org/10.1111/ene.13043 .
doi: 10.1111/ene.13043
pubmed: 27297659
Religa D, Fereshtehnejad SM, Cermakova P, Edlund AK, Garcia-Ptacek S, Granqvist N. SveDem, the Swedish Dementia Registry—a tool for improving the quality of diagnostics, treatment and care of dementia patients in clinical practice. PLoS ONE. 2015;10(2):1–14. https://doi.org/10.1371/journal.pone.0116538 .
doi: 10.1371/journal.pone.0116538
Wettermark B, Hammar N, Fored C, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug Register-Opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2006;16(7):726–35. https://doi.org/10.1002/pds.1294 .
doi: 10.1002/pds.1294
Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011. https://doi.org/10.1186/1471-2458-11-450 .
doi: 10.1186/1471-2458-11-450
pubmed: 21658213
pmcid: 3142234
Meyer AC, Sandström G, Modig K. Nationwide data on home care and care home residence: presentation of the Swedish Social Service Register, its content and coverage. Scand J Public Health. 2022;50(7):946–58. https://doi.org/10.1177/14034948211061016 .
doi: 10.1177/14034948211061016
pubmed: 34965796
Cognitive impairment in suspected dementia - National clinical knowledge support. (n.d.). Retrieved 25 August 2023, from https://www.nationelltklinisktkunskapsstod.se/kunskapsstod/vardforlopp/?uuid=c38fa4a0-a3ec-4b15-8aec-beca2fefe69b . Accessed 29 Apr 2024.
Socialstyrelsen. (2017). Nationella riktlinjer 2017. Vård och omsorg vid demenssjukdom - stöd för styrning och ledning. [National guidelines for care in cases of dementia].
World Health Organization. (n.d.). ICD-10 Version:2016. Retrieved 28 July 2022, from https://icd.who.int/browse10/2016/en# . Accessed 29 Apr 2024.
Calderón-Larrañaga A, Vetrano DL, Onder G, Gimeno-Feliu LA, Coscollar-Santaliestra C, Carfí A, et al. Assessing and measuring chronic multimorbidity in the older population: a proposal for its operationalization. J Gerontol A Biol Sci Med Sci. 2017;72(10):1417–23. https://doi.org/10.1093/gerona/glw233 . Accessed 29 Apr 2024.
doi: 10.1093/gerona/glw233
pubmed: 28003375
Socialstyrelsen. (2012). Äldre – vård och omsorg den 1 oktober 2012. Kommunala insatser enligt socialtjänstlagen samt hälso- och sjukvårdslagen, 2012. Retrieved from http://www.socialstyrelsen.se . Accessed 29 Apr 2024.
Stockholms stad. (2020). Stöd vid funktionsnedsättning. Retrieved 29 April 2024, from https://funktionsnedsattning.stockholm/olika-former-av-insatser/stod-i-hemmet/boendestod/ . Accessed 29 Apr 2024.
Socialstyrelsen. (2024). Vård och omsorg för äldre Lägesrapport 2024. Retrieved from https://www.socialstyrelsen.se/aktuellt/arets-lagesrapport--vard-och-omsorg-for-aldre/ . Accessed 29 Apr 2024.
Sveriges Kommuner och Regioner. (2023). Cost per patient, KPP. SKR. Retrieved 28 March 2024, from https://skr.se/skr/halsasjukvard/ekonomiavgifter/kostnadperpatientkpp.1076.html . Accessed 29 Apr 2024.
RKA. (n.d.). Kolada - en tjänst från RKA. Retrieved 26 February 2024, from https://www.kolada.se/verktyg/fri-sokning/?kpis=35480,35484,41297,44440,76370,83908&years=30200,30199,30198&municipals=2328&rows=municipal,kpi&visualization=bar-chart . Accessed 29 Apr 2024.
Lin PJ, Zhong Y, Fillit HM, Chen E, Neumann PJ. Medicare expenditures of individuals with Alzheimer’s disease and related dementias or mild cognitive impairment before and after diagnosis. J Am Geriatr Soc. 2016;64(8):1549–57. https://doi.org/10.1111/jgs.14227 .
doi: 10.1111/jgs.14227
pubmed: 27295430
Vermunt L, Sikkes SA, van den Hout A, Handels R, Bos I, van der Flier WM, et al. Duration of preclinical, prodromal and dementia Alzheimer disease stages in relation to age, sex, and APOE genotype. Alzheimers Dement. 2019;15(7):888–98. https://doi.org/10.1016/j.jalz.2019.04.001 .
doi: 10.1016/j.jalz.2019.04.001
pubmed: 31164314
Tate AE, Bouteloup V, van Maurik IS, Jean D, Mank A, Speh A, et al. Predicting sojourn times across dementia disease stages, institutionalization, and mortality. Alzheimers Dement. 2024;20(2):809–18. https://doi.org/10.1002/ALZ.13488 .
doi: 10.1002/ALZ.13488
pubmed: 37779086
Robinson R, Rentz D, Andrews J, Zagar A, Kim Y, Bruemmer V, et al. Costs of early stage Alzheimer’s disease in the United States: cross-sectional analysis of a prospective cohort study (GERAS-US) 1. J Alzheimers Dis. 2020;75(2):437–50. https://doi.org/10.3233/JAD-191212 .
doi: 10.3233/JAD-191212
pubmed: 32250304
pmcid: 7306889
Chandler J, Kubisiak J. Clinical and economic assessment in early-stage dementia by severity and amyloid-status: a 5-year retrospective claims study of GERAS-US patients. J Alzheimers Dis. 2023;91:753–65. https://doi.org/10.3233/JAD-220415 .
doi: 10.3233/JAD-220415
pubmed: 36502319
pmcid: 9912735
Schwarzkopf L, Menn P, Leidl R, Wunder S, Mehlig H, Marx P, et al. Excess costs of dementia disorders and the role of age and gender-an analysis of German health and long-term care insurance claims data. BMC Health Serv Res. 2012. https://doi.org/10.1186/1472-6963-12-165 .
doi: 10.1186/1472-6963-12-165
pubmed: 22713212
pmcid: 3425320
Sontheimer N, Konnopka A, König H-H. The excess costs of dementia: a systematic review and meta-analysis. J Alzheimers Dis. 2021;83(1):333–54. https://doi.org/10.3233/JAD-210174 .
doi: 10.3233/JAD-210174
pubmed: 34334395
Sm-Rahman A, Meinow B, Hydén LC, Kelfve S. Long-term care use among people living with dementia: a retrospective register-based study from Sweden. BMC Geriatr. 2022. https://doi.org/10.1186/s12877-022-03713-0 .
doi: 10.1186/s12877-022-03713-0
pubmed: 36572863
pmcid: 9793631
Wimo A, Handels R, Elmståhl S, Fagerström C, Fratiglioni L, Isaksson U, et al. Informell och formell vård hos äldre personer i ordinärt boende—förändringar och samspel över tid 2001–2015 i SNAC projektet. Nordanstig, Sverige. 2020. https://www.snac-k.se/wp-content/uploads/2021/03/SNAC_Informell_formell_vard_2020.pdf . Accessed 29 Apr 2024.
Leicht H, Heinrich S, Heider D, Bachmann C, Bickel H, van den Bussche H, et al. Net costs of dementia by disease stage. Acta Psychiatr Scand. 2011;124(5):384–95. https://doi.org/10.1111/j.1600-0447.2011.01741.x .
doi: 10.1111/j.1600-0447.2011.01741.x
pubmed: 21838738
Nordberg G, Wimo A, Jönsson L, Kåreholt I, Sjölund B-M, Lagergren M, Von Strauss E. Time use and costs of institutionalised elderly persons with or without dementia: results from the Nordanstig cohort in the Kungsholmen Project-a population based study in Sweden. Int J Geriatr Psychiatry. 2007;22(7):639–48. https://doi.org/10.1002/gps.1724 .
doi: 10.1002/gps.1724
pubmed: 17225239
Åkerborg Ö, Lang A, Wimo A, Sköldunger A, Fratiglioni L, Gaudig M, Rosenlund M. Cost of dementia and its correlation with dependence. J Aging Health. 2016;28(8):1448–64. https://doi.org/10.1177/0898264315624899/FORMAT/EPUB .
doi: 10.1177/0898264315624899/FORMAT/EPUB
pubmed: 26818587
Stolz Id E, Mayerl H, Va E, Sky R, Freidl W. Individual and country-level determinants of nursing home admission in the last year of life in Europe. PLoS ONE. 2019;14(3):e0213787. https://doi.org/10.1371/journal.pone.0213787 .
doi: 10.1371/journal.pone.0213787
Lennarth J, Pär S. Quality and cost-effectiveness in long-term care and dependency prevention. 2017. https://aldrecentrum.se/enskilt-dokument/quality-and-cost-effectiveness-in-long-term-care-and-dependency-prevention/ . Accessed 29 Apr 2024.
Beam CR, Kaneshiro C, Jang JY, Reynolds CA, Pedersen NL, Gatz M. Differences between women and men in incidence rates of dementia and Alzheimer’s disease. J Alzheimers Dis. 2018;64(4):1077–83. https://doi.org/10.3233/JAD-180141 .
doi: 10.3233/JAD-180141
pubmed: 30010124
pmcid: 6226313
Brooker D, Peel E, Erol R. Women and dementia. Alzheimer’s Disease International. 2015. https://www.alzint.org/resource/women-and-dementia-a-global-research-review/ . Accessed 29 Apr 2024.
SM-Rahman A, Meinow B, Hydén LC, Kelfve S. Patterns of long-term care utilization during the last five years of life among Swedish older adults with and without dementia. PLoS ONE. 2023. https://doi.org/10.1371/journal.pone.0286930 .
doi: 10.1371/journal.pone.0286930
pubmed: 37874798
pmcid: 10597483
Cermakova P, Nelson M, Secnik J, Garcia-Ptacek S, Johnell K, Fastbom J, et al. Living alone with Alzheimer’s disease: data from SveDem, the Swedish Dementia Registry. J Alzheimers Dis. 2017;58(4):1265–72. https://doi.org/10.3233/JAD-170102 .
doi: 10.3233/JAD-170102
pubmed: 28550260
pmcid: 5523910
Meinow B, Wastesson JW, Kåreholt Phd I, Kelfve Phd S. Long-term care use during the last 2 years of life in Sweden: implications for policy to address increased population aging. J Am Med Dir Assoc. 2020;21(6):799–805. https://doi.org/10.1016/j.jamda.2020.01.003 .
doi: 10.1016/j.jamda.2020.01.003
pubmed: 32081681
Wimo A, Jonsson L, Zbrozek A. The Resource Utilization in Dementia (RUD) instrument is valid for assessing informal care time in community-living patients with dementia. J Nutr Health Aging. 2010;14(8):685–90.
doi: 10.1007/s12603-010-0316-2
pubmed: 20922346